Core Viewpoint - Sanofi is actively contributing to the "Healthy China" initiative by showcasing innovative drugs and vaccines at the 8th China International Import Expo, focusing on major health issues such as cardiovascular diseases, metabolic disorders, respiratory diseases, and cancer [1][2]. Group 1: Innovative Products and Collaborations - Sanofi presented ten first-in-class or best-in-class innovative products, including two groundbreaking cardiovascular therapies making their global debut: Afikaytai tablets and Pulesiran sodium injection [2][3]. - The company is deepening strategic collaborations with local partners to enhance the pharmaceutical innovation ecosystem in China, exemplified by the establishment of the Sanofi-Kaihui Pharmaceutical Innovation Fund [2][3]. Group 2: Commitment to Local Development - Sanofi has been accelerating the approval and market entry of innovative drugs in China, evidenced by the successful launch of multiple products, including the first targeted therapy for immune-mediated thrombotic thrombocytopenic purpura [4][5]. - The company is transitioning from being an exhibitor to an investor, increasing its investment in local production and innovation, including a recent €1 billion investment in a Beijing insulin raw material project [6].

Core Viewpoint - Sanofi's innovative drug Cablivi has received approval from China's National Medical Products Administration (NMPA) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults and adolescents aged 12 and above weighing at least 40 kg [1] Group 1 - Cablivi is the first and only targeted nanobody drug approved for the treatment of iTTP globally [1] - The drug aims to provide faster disease control, reduce related mortality, worsening, or major thrombotic events, and prevent recurrence [1] - Cablivi offers a more effective and safer treatment option for patients [1]